Ipilimumab is a CTLA-4 blocking antibody that was approved by the
U.S. FDA in March 2011 for the treatment of unresectable or metastatic
melanoma. Therefore, ipilimumab has an indirect effect on tumors that is
mediated through blockade of CTLA-4 negative signaling and
augmentation of T-cell activity. It is one of a handful of
immunostimulatory drugs (e.g., aldesleukin and interferon alfa-2b) now approved for cancer therapy.
용도
Treatment of
oncology disease and HIV infection.
부작용
The more common side effects of ipilimumab include Bloody, black, or tarry stools; bone pain; chest pain or tightness; constipation; cough; depressed mood; diarrhea; dry skin and hair; feeling cold; fever; hair loss; heartburn; hoarseness or husky voice; indigestion; itching, skin rash; muscle cramps; nausea; pain in the arms or legs; severe stomach pain, cramping, or burning; slowed heartbeat; sneezing; sore throat; trouble breathing; unusual tiredness or weakness; vomiting; vomiting of material that looks like coffee grounds, severe and continuing; watery or bloody diarrhea.
